Sciele complete Phase III trial of Glycopyrrolate for Moderate-to-Severe Drooling « GPCR News

Tags
5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
July 2008

M T W T F S S

« Jun Aug »

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

Sciele complete Phase III trial of Glycopyrrolate for Moderate-to-Severe Drooling

Posted on July 8, 2008 by crimsoncanary

Sciele Pharma have completed a phase III trial for Glycopyrrolate Liquid for the treatment of chronic, moderate-to-severe drooling in pediatric patients

Filed under: Uncategorized | Tagged: antagonist, Glycopyrrolate, M3, Muscarinic, Muscarinic M3, phase III, Robinul, Sciele

« FDA lift clinical hold on Adolors Entereg (alvimopan) program for chronic opioid bowel dysfunction (OBD). Emisphere publish data on Oral GLP-1 »

Leave a Reply